蛋白酶体作为治疗造血系统疾病的新的靶点
Proteasome Inhibition: A New Approach to the Treatment of Hematologic Disease
This program is sponsored by the University of Nebraska Medical Center, Center for Continuing Education, and supported by Millennium Pharmaceuticals, Inc.
Proteasomes are responsible for the degradation of intracellular proteins involved in cell proliferation, apoptosis, adhesion, angiogenesis, and signal transduction. In cancer cells, proteasome inhibitors can cause apoptosis and suppress tumor growth, spread, and angiogenesis. The symposium will discuss the antitumor mechanism of action of proteasome inhibition and present trial results for bortezomib in multiple myeloma and lymphoma. The rationale for combining proteasome inhibitors with chemotherapy and the role of pharmacogenomic studies in patients with hematologic malignancies will be highlighted.
For more information, contact Heather Steelman, AOI Communications, Inc.
Phone: (203) 406-1725, ext. 2508
Fax: (203) 406-1726
E-mail: h.steelman@accessoncology.com, 百拇医药
This program is sponsored by the University of Nebraska Medical Center, Center for Continuing Education, and supported by Millennium Pharmaceuticals, Inc.
Proteasomes are responsible for the degradation of intracellular proteins involved in cell proliferation, apoptosis, adhesion, angiogenesis, and signal transduction. In cancer cells, proteasome inhibitors can cause apoptosis and suppress tumor growth, spread, and angiogenesis. The symposium will discuss the antitumor mechanism of action of proteasome inhibition and present trial results for bortezomib in multiple myeloma and lymphoma. The rationale for combining proteasome inhibitors with chemotherapy and the role of pharmacogenomic studies in patients with hematologic malignancies will be highlighted.
For more information, contact Heather Steelman, AOI Communications, Inc.
Phone: (203) 406-1725, ext. 2508
Fax: (203) 406-1726
E-mail: h.steelman@accessoncology.com, 百拇医药